HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Ectopic atrial tachycardia — Clinical Guidelines

Overview

Ectopic atrial tachycardia (EAT) is a type of supraventricular tachycardia characterized by rapid heartbeats originating from ectopic foci within the atria, commonly seen in pediatric populations and often resistant to initial medical therapy 1 2.

Diagnosis

Electrocardiogram (ECG) showing characteristic tachycardia patterns with ectopic P waves 1 2.

Echocardiography to assess for tachycardia-induced cardiomyopathy (TIC) and ventricular function 1 2.

Electrophysiology studies to map the origin and mechanism of tachycardia 2 3.

Management

First-line treatments: Antiarrhythmic drugs such as sotalol and propafenone; intravenous encainide and flecainide show efficacy in terminating episodes 1 5.

Adjunctive treatments: Radiofrequency catheter ablation (RFCA) is highly effective for persistent or resistant cases, with high success rates and low recurrence 2 3 4.

Specific drug dosing: Intravenous encainide doses ranged from 0.3 to 2.0 mg/kg, oral encainide 150-225 mg/day 5.

Special Populations

Pediatrics: EAT is common in children, often resistant to antiarrhythmic drugs; RFCA is preferred for persistent cases 1 2 3 4.

Comorbidities: Tachycardia-induced cardiomyopathy (TIC) noted in 22.6% of pediatric cases, with significant improvement post-ablation 1 2.

Key Recommendations

Consider radiofrequency catheter ablation (RFCA) as first-line treatment for persistent or drug-resistant ectopic atrial tachycardia (EAT) in children (Evidence: Strong 2 3 4).

Monitor for tachycardia-induced cardiomyopathy (TIC) in pediatric patients with EAT and evaluate ventricular function regularly (Evidence: Moderate 1 2).

Use combination therapy with sotalol and propafenone for initial pharmacological management of EAT in pediatric patients (Evidence: Moderate 1).

Evaluate the origin of EAT via electrophysiologic studies to guide precise catheter ablation targeting (Evidence: Moderate 2 3).

References

1 Ge H, Li X, Liu H, Jiang H. Predictors of Pharmacological Therapy of Ectopic Atrial Tachycardia in Children. Pediatric cardiology 2017. link 2 Toyohara K, Fukuhara H, Yoshimoto J, Ozaki N, Nakamura Y. Electrophysiologic studies and radiofrequency catheter ablation of ectopic atrial tachycardia in children. Pediatric cardiology 2011. link 3 Cummings RM, Mahle WT, Strieper MJ, Campbell RM, Costello L, Balfour V et al.. Outcomes following electroanatomic mapping and ablation for the treatment of ectopic atrial tachycardia in the pediatric population. Pediatric cardiology 2008. link 4 Walsh EP, Saul JP, Hulse JE, Rhodes LA, Hordof AJ, Mayer JE et al.. Transcatheter ablation of ectopic atrial tachycardia in young patients using radiofrequency current. Circulation 1992. link 5 Kuck KH, Kunze KP, Schlüter M, Duckeck W. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia. The American journal of cardiology 1988. link90014-8)

Ectopic atrial tachycardia